Faeth Therapeutics, Inc. Earnings Per Share, Basic and Diluted
Faeth Therapeutics, Inc. (FTH) reported Earnings Per Share, Basic and Diluted of -$0.34 per share for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-08-09
- Faeth Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-06-30 was -$0.34.
- Faeth Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.40.
- Faeth Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.31.
- Faeth Therapeutics, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.32.
- Faeth Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2021 was -$1.33.
- Faeth Therapeutics, Inc. earnings per share, basic and diluted for fiscal 2020 was -$12.53.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$0.34 10-Q · filed 2022-08-09 | -$0.75 10-Q · filed 2022-08-09 | -$1.05 derived: net income ÷ weighted average shares · filed 2023-08-03 | -$1.37 derived: net income ÷ weighted average shares · filed 2023-08-03 |
| 2022-03-31 | -$0.40 10-Q · filed 2022-05-10 | -$0.71 derived: net income ÷ weighted average shares · filed 2023-05-09 | -$1.03 derived: net income ÷ weighted average shares · filed 2023-05-09 | -$1.35 derived: net income ÷ weighted average shares · filed 2023-05-09 |
| 2021-12-31 | -$0.31 derived: net income ÷ weighted average shares · filed 2023-03-29 | -$0.62 derived: net income ÷ weighted average shares · filed 2023-03-29 | -$0.94 derived: net income ÷ weighted average shares · filed 2023-03-29 | -$1.33 10-K · filed 2022-03-15 |
| 2021-09-30 | -$0.32 10-Q · filed 2021-11-10 | -$0.64 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$1.03 10-Q · filed 2021-11-10 | -$1.59 derived: net income ÷ weighted average shares · filed 2022-11-08 |
| 2021-06-30 | -$0.32 10-Q · filed 2022-08-09 | -$0.72 10-Q · filed 2022-08-09 | -$1.34 derived: net income ÷ weighted average shares · filed 2022-08-09 | -$2.13 derived: net income ÷ weighted average shares · filed 2022-08-09 |
| 2021-03-31 | -$0.42 10-Q · filed 2022-05-10 | -$1.26 derived: net income ÷ weighted average shares · filed 2022-05-10 | -$2.46 derived: net income ÷ weighted average shares · filed 2022-05-10 | -$3.87 derived: net income ÷ weighted average shares · filed 2022-05-10 |
| 2020-12-31 | -$2.78 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$5.78 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$8.80 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$12.53 10-K · filed 2022-03-15 |
| 2020-09-30 | -$3.00 10-Q · filed 2021-11-10 | -$6.02 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$9.82 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$3.02 10-Q · filed 2021-08-11 | -$6.87 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$4.00 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |